glp 1 receptor agonist drugs glp-1_analogs [TUSOM GLP-1 receptor agonists | How
Description
doi: 10.1016/j.molmet.2020.100990
Nutrition and Metabolism 13, 92
Cell Metab 30 , 987996.e6 (2019)
Patients were followed from 1 year after cohort entry until a diagnosis of incident adverse CVEs, switch to a comparator drug, any cause of death or the end of the study (30 September 2022), whichever occurred first
In fact, most studies suggest that function improves with significant weight loss
Although overall findings support a cardioprotective effect of GLP-1 RAs, the ITCA 650 trial showed directionally higher hazard ratios for several outcomes
